IBA (Ion Beam Applications SA), a provider of proton therapy solutions for the treatment of cancer, is pleased to announce a co-marketing agreement in North America with Nelco Worldwide, a provider of radiation shielding products and solutions to offer custom, modular radiation shielding solutions for ProteusONE.
The ProteusONE has been developed by IBA to allow patients worldwide access to proton therapy. The compact, single-treatment-room proton therapy solution is smaller than existing standard systems, making it more affordable and, therefore, more accessible to clinical institutions. ProteusONE incorporates the latest in proton therapy technology, including Pencil Beam Scanning (PBS) and Cone-Beam CT (CBCT).
The Agilis1TM system is a custom, pre-engineered, modular solution that is exclusively developed by NELCO, to enable IBA to reduce time and costs associated with the complex shielding requirements of the ProteusONE equipment. “Our primary motivation for creating this first-of-its kind solution is to allow cancer centers to start treating patients sooner,” said Rick LeBlanc, president and CEO of NELCO Worldwide.
“We chose NELCO as our preferred vendor because of their excellent reputation and track record in developing and deploying shielding solutions for the radiotherapy market,” said Jason Koshnitsky, Product Director of IBA North America. “Their custom Agilis offering was specifically developed for our ProteusONE with the intention of reducing time and cost associated with building a proton therapy center.”Back To Top
IBA, Nelco to offer compact, proton therapy, modular shielding solutions in North America. Appl Rad Oncol.